On Thursday, ImmunoGen, Inc. (NASDAQ:IMGN)’s shares declined -1.25% to $14.22.
ImmunoGen, Inc. (IMGN) declared the first presentation of findings with the Company’s CD37-targeting ADC, IMGN529, in combination with the CD20-targeting antibody, rituximab (Rituxan®), in preclinical assessments. These data are being presented in a poster at the 13th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland (abstract #P-274).
Among the findings being presented are:
- IMGN529 exhibits strong synergy with rituximab and other CD20-targeting antibodies in cell lines representative of an array of non-Hodgkin lymphoma (NHL) subtypes, counting both GCB and ABC diffuse large B-cell lymphoma (DLBCL);
- Compriseent with the in vitro findings, the combination of IMGN529 and rituximab was highly active against DLBCL modelsin vivo;
- Synergy also was seen in vitroin a model representative of “double hit” lymphoma, a particularly difficult-to-treat type of DLBCL characterized by deregulation of two different genes, BCL2 (or BCL6) and MYC; and
- Both IMGN529’s antibody component and its DM1 payload contributed to its synergistic activity with rituximab.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s shares dropped -2.27% to $6.89.
Spectrum Pharmaceuticals, Inc. (SPPI) was a big mover last session, as its shares rose over 10% on the day. The upside came on the back of an encouraging declarement by an activist that the company could fetch more than $7.95 a share in a sale. This led to more shares changing hands than in a normal session. Yesterday’s rally continues the recent uptrend for the company, as the stock is now up over 11% in the past one-month time frame.
Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent over dosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
At the end of Thursday’s trade, Citrix Systems, Inc. (NASDAQ:CTXS)‘s shares dipped -0.09% to $71.61.
Citrix Systems, Inc. (CTXS) declared that Gartner, Inc. has positioned Citrix in the Leaders quadrant of the 2015 Magic Quadrant for Enterprise Mobility Administration (EMM) Suites report1 for the fourth successive year. The report evaluated XenMobile® enterprise mobility administration (EMM) solution, the most comprehensive and flexible solution for managing apps, data and devices with a broad set of business optimized mobile apps.
According to Gartner, “leaders have the highest product revenue in the EMM market, several years of proven customer implementations, customer mind share, and extensive partnerships with channel and other technology providers. They have the most complete products in the EMM market. Leaders also demonstrate commitment to the EMM market. Their companies are aligned with the trends of the EMM market. They possess product road maps, which (if executed upon) would establish continued differentiation in the market. Leaders also demonstrate commitment to the EMM market. Overall, they have a strategy that creates a high likelihood of success in this market.”
Citrix Systems, Inc. provides virtualization, mobility administration, networking, and Software as a Service solutions worldwide. The company’s Enterprise and Service Provider division offers XenMobile Enterprise, a solution to manage mobile devices, apps, and data; XenDesktop, a desktop virtualization system that gives customers the flexibility to deliver desktops and applications as cloud services; Citrix XenApp that allows Windows applications to be delivered as cloud services to Android and iOS mobile devices, Macs, PCs, and thin clients; and Citrix Workspace Suite, a business mobility solution that delivers the user experience for any app or desktop.
Fiserv Inc (NASDAQ:FISV), ended its Thursday’s trading session with -0.14% loss, and closed at $84.88.
Fiserv, Inc. (FISV), a leading global provider of financial services technology solutions, declared recently that PBC Credit Union, based in West Palm Beach, Florida, has expanded its long-term relationship with Fiserv, upgrading its DataSafe® account processing platform and adding integrated digital solutions to enhance member services. The credit union added Mobiliti™ for mobile banking, Loancierge® for Credit Unions for automated lending, Wisdom™: Accounting for comprehensive accounting and Wisdom: 5300 Call Report Assistant for call report functionality.
The credit union has also renewed its commitment to the CheckFree® RXP® electronic bill payment solution and credit and debit processing from Fiserv.
Fiserv, Inc., together with its auxiliaries, provides financial services technology worldwide. The company’s Payments and Industry Products segment provides debit, credit, and prepaid card processing and services; electronic bill payment and presentment services; Internet and mobile banking software and services; person-to-person payment services; and other electronic payments software and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
